Michigan Cannabis Market: Regulations, Sales Data, and Industry Trends

Executive Summary

Michigan operates one of the nation's most dynamic cannabis markets, generating over $3 billion in annual sales since adult-use legalization in 2018, but faces mounting challenges from oversupply, price compression, and facility consolidation. The state's regulatory framework, established under the Michigan Regulation and Taxation of Marihuana Act (MRTMA), created a dual-track system serving both medical patients under the Michigan Medical Marihuana Act (MMMA) and recreational consumers. As of May 2026, Michigan hosts approximately 1,800 active cannabis licenses across cultivation, processing, testing, and retail operations, making it the fifth-largest legal cannabis market in the United States by revenue. Recent facility closures, including a Lansing cultivation operation that laid off 94 workers in May 2026, signal market maturation pressures as wholesale flower prices have declined from peak levels of $2,400 per pound in 2020 to approximately $800-$1,000 per pound in 2026. The Michigan Cannabis Regulatory Agency (CRA), operating under the Department of Licensing and Regulatory Affairs, oversees all commercial cannabis activity while municipalities retain local control authority to prohibit or restrict operations within their jurisdictions.

Why This Matters

Michigan's cannabis market directly impacts 35,000 employees, 500,000 registered medical patients, and generates approximately $290 million in annual state tax revenue. The state's experience with rapid market expansion and subsequent consolidation offers critical lessons for emerging markets nationwide. Michigan's regulatory approach—combining state oversight with municipal opt-in authority—has created a patchwork of access that varies dramatically by county. As of 2026, approximately 1,400 of Michigan's 1,773 municipalities have opted out of allowing adult-use cannabis businesses, concentrating operations in urban centers and creating cannabis deserts in rural areas. For patients, Michigan maintains one of the nation's most affordable medical cannabis programs, with average eighth-ounce prices of $25-$35 compared to $45-$60 in limited-license states like Illinois and New York. This price accessibility stems from the state's open licensing structure, which imposes no artificial caps on cultivation or retail licenses beyond standard regulatory requirements. For investors and operators, Michigan represents both opportunity and cautionary tale. The state's low barriers to entry attracted significant capital from 2019-2022, but oversupply conditions have forced margin compression across the supply chain. Wholesale prices for premium indoor flower declined 58% from 2020 to 2026, while retail prices dropped approximately 35% over the same period. Multi-state operators including Cresco Labs, Green Thumb Industries, and Verano Holdings maintain significant Michigan footprints but have scaled back expansion plans as market conditions tightened. The May 2026 Lansing facility closure exemplifies broader consolidation trends. According to Michigan CRA data, approximately 120 cultivation licenses have been surrendered or revoked since January 2024, representing roughly 12% of the state's peak cultivation capacity. This contraction affects communities that welcomed cannabis operations for tax revenue and employment, with layoffs concentrated in mid-Michigan manufacturing corridors that previously relied on automotive industry jobs.

Background and History

Michigan's cannabis legalization unfolded across two decades, beginning with medical authorization in 2008 and culminating in one of the nation's most permissive adult-use frameworks by 2019.

Medical Cannabis Foundation (2008-2016)

Michigan voters approved the Michigan Medical Marihuana Act (MMMA) on November 4, 2008, with 63% support, making Michigan the 13th state to legalize medical cannabis. The MMMA, codified at MCL 333.26421 et seq., established a patient-caregiver model allowing registered patients to possess up to 2.5 ounces of usable cannabis and cultivate up to 12 plants. Caregivers could serve up to five patients, effectively permitting small-scale cultivation of 60 plants plus 12 for personal use. The law's implementation proved contentious. The Michigan Supreme Court issued multiple rulings clarifying the MMMA's scope, including People v. McQueen (2013), which held that the act's protections did not extend to all forms of cannabis derivatives, and Ter Beek v. City of Wyoming (2014), which affirmed municipal authority to zone medical cannabis operations. By 2016, Michigan had registered approximately 218,000 medical patients but lacked a regulated commercial supply chain, creating a gray market of caregiver-to-patient transfers.

Medical Licensing Framework (2016-2018)

Recognizing the need for commercial regulation, the Michigan Legislature enacted the Medical Marihuana Facilities Licensing Act (MMFLA) in September 2016, effective December 2017. The MMFLA, codified at MCL 333.27101 et seq., created five license classes: growers (Class A: 500 plants; Class B: 1,000 plants; Class C: 1,500 plants), processors, provisioning centers (dispensaries), secure transporters, and safety compliance facilities (testing labs). The Bureau of Medical Marihuana Regulation, later renamed the Cannabis Regulatory Agency, began accepting applications in December 2017. The first provisioning center licenses were issued in March 2018, with approximately 220 medical retail locations operational by November 2018. This regulatory buildout occurred simultaneously with the adult-use legalization campaign, creating infrastructure that would later serve dual markets.

Adult-Use Legalization (2018)

On November 6, 2018, Michigan voters approved Proposal 1, the Michigan Regulation and Taxation of Marihuana Act (MRTMA), with 56% support. The MRTMA, codified at MCL 333.27951 et seq., legalized possession of up to 2.5 ounces in public and 10 ounces at home for adults 21 and older, along with home cultivation of up to 12 plants. The law took effect December 6, 2018, immediately legalizing possession and home growing. Commercial sales required regulatory implementation. The Cannabis Regulatory Agency began accepting adult-use license applications in November 2019, prioritizing existing medical operators for the first 12 months under a "stacking" provision that allowed medical licensees to add adult-use endorsements. The first adult-use retail sales occurred on December 1, 2019, at Ann Arbor dispensaries.

Market Expansion and Maturation (2020-2026)

Michigan's adult-use market grew explosively from 2020-2022. Total cannabis sales (medical and adult-use combined) reached $1.8 billion in 2020, $2.3 billion in 2021, and peaked at $3.2 billion in 2022 according to CRA data. Adult-use sales surpassed medical sales in mid-2021 and represented approximately 75% of total market volume by 2023. License issuance accelerated through 2021, with the state approving over 1,200 cultivation licenses by year-end. This cultivation capacity far exceeded initial demand projections, creating oversupply conditions by late 2021. Wholesale flower prices, which averaged $2,400 per pound in early 2020, declined to $1,600 by late 2021 and $1,000 by mid-2023. The market entered a consolidation phase in 2023-2024. Several factors converged: federal 280E tax burdens (26 U.S.C. § 280E prohibits standard business deductions for Schedule I substances), limited access to traditional banking, and price compression from oversupply. Smaller operators struggled to maintain profitability, leading to license surrenders, foreclosures, and acquisitions by larger MSOs. By 2025, Michigan's market stabilized around $3 billion in annual sales with approximately 1,800 active licenses. The May 2026 Lansing facility closure reflects ongoing rationalization as operators adjust capacity to sustainable demand levels.

Key Players

Michigan Cannabis Regulatory Agency (CRA)

The CRA, operating within the Department of Licensing and Regulatory Affairs, serves as the state's primary cannabis regulator. Executive Director Brian Hanna has led the agency since 2022, overseeing approximately 120 staff members responsible for licensing, compliance, enforcement, and social equity programs. The CRA maintains regulatory authority under both the MMFLA and MRTMA, conducting facility inspections, investigating complaints, and imposing sanctions ranging from fines to license revocation.

Multi-State Operators

Several national cannabis companies maintain significant Michigan operations. Green Thumb Industries operates approximately 13 RISE dispensaries across the state and holds cultivation licenses in multiple municipalities. Cresco Labs operates Sunnyside dispensaries and cultivation facilities, while Verano Holdings maintains MÜV retail locations and processing operations. These MSOs collectively control an estimated 15-20% of Michigan's retail market share as of 2026.

Michigan-Based Operators

Locally-founded companies remain competitive forces. Exclusive Brands, based in Ann Arbor, operates cultivation, processing, and retail operations with brands including Kola and Cloud Cover. Pleasantrees, headquartered in East Lansing, maintains vertically integrated operations across cultivation, manufacturing, and retail. Gage Cannabis Co., founded in Michigan before acquisition by TerrAscend in 2021, continues operating retail and cultivation facilities.

Municipal Governments

Local governments exercise significant control over cannabis operations through opt-in authority granted by the MRTMA. Cities including Detroit, Ann Arbor, Lansing, Grand Rapids, and Traverse City have embraced cannabis commerce, establishing local licensing processes and collecting municipal taxes. Detroit's adult-use program, launched in 2022, prioritizes legacy residents and social equity applicants. Conversely, communities including Livonia, Sterling Heights, and numerous rural townships have opted out, citing concerns about public health and community character.

Advocacy Organizations

The Michigan Cannabis Industry Association represents licensed operators, advocating for regulatory reforms and market stability. The Michigan Cannabis Manufacturers Association focuses on cultivation and processing sector interests. Patient advocacy groups including Michigan NORML and the Michigan chapter of Americans for Safe Access continue advocating for patient protections and expanded access.

Legal and Regulatory Framework

Michigan's cannabis regulation operates through parallel medical and adult-use statutes, both subject to municipal opt-in authority and comprehensive state oversight. The Michigan Medical Marihuana Act (MCL 333.26421 et seq.) and Medical Marihuana Facilities Licensing Act (MCL 333.27101 et seq.) govern medical cannabis. Patients must obtain physician certification for one of several qualifying conditions, including cancer, glaucoma, HIV/AIDS, hepatitis C, ALS, Crohn's disease, agitation of Alzheimer's disease, nail patella, chronic pain, and PTSD. The registry identification card, issued by the CRA, costs $40 annually ($25 for Medicaid recipients and veterans). As of March 2026, Michigan had approximately 500,000 active medical cardholders. The Michigan Regulation and Taxation of Marihuana Act (MCL 333.27951 et seq.) governs adult-use cannabis. Key provisions include: - **Possession limits**: 2.5 ounces on person, 10 ounces at residence, 12 plants per household - **Consumption restrictions**: prohibited in public, in motor vehicles, and on federal property - **Taxation**: 10% excise tax on adult-use sales (medical sales exempt), plus 6% state sales tax - **Local control**: municipalities may prohibit or limit cannabis establishments through ordinance - **Social equity**: CRA must promote and encourage participation by communities disproportionately impacted by cannabis prohibition License types under the MRTMA include Class A growers (100 plants), Class B growers (500 plants), Class C growers (2,000 plants), excess growers (no plant limit, available since 2022), processors, provisioning centers (retail), secure transporters, safety compliance facilities, and designated consumption establishments (social consumption lounges, authorized since 2021 but with limited implementation). The CRA enforces comprehensive regulations covering security, testing, packaging, labeling, advertising, and record-keeping. All cannabis products must undergo testing for potency, pesticides, heavy metals, microbials, and mycotoxins at state-licensed laboratories. Testing requirements are codified in administrative rules at Mich. Admin. Code R. 333.101 et seq. Federal law remains a complicating factor. Cannabis remains a Schedule I controlled substance under the Controlled Substances Act (21 U.S.C. § 812), creating conflicts with federal banking regulations, tax law (26 U.S.C. § 280E), and immigration law. Michigan operators cannot deduct ordinary business expenses on federal tax returns, significantly increasing effective tax rates. Most banks decline to serve cannabis businesses due to federal money laundering concerns under 18 U.S.C. § 1956, forcing many operators to conduct cash-intensive operations.

Market and Business Implications

Michigan's cannabis market generated approximately $3.1 billion in total sales during 2025, with adult-use sales representing $2.3 billion and medical sales $800 million, but operators face sustained margin pressure from oversupply and regulatory costs. Wholesale pricing dynamics reveal market stress. Premium indoor flower that commanded $2,400 per pound in early 2020 now trades at $800-$1,000 per pound as of May 2026. Mid-grade flower sells for $500-$700 per pound, while outdoor and greenhouse flower trades at $300-$500 per pound. These price levels approach or fall below production costs for many cultivators, particularly those operating smaller facilities with higher per-unit costs. Retail pricing has followed wholesale trends downward but with less severe compression. Average retail prices for an eighth-ounce of flower declined from approximately $45-$50 in 2020 to $30-$35 in 2026, a 30-35% decrease. Retail margins have compressed from 50-60% gross margins in 2020 to 35-45% in 2026 as competition intensified and wholesale costs remained elevated relative to retail price declines. The Lansing cultivation facility closure announced in May 2026 exemplifies the consolidation pressures facing mid-sized operators. The facility, which employed 94 workers, reportedly struggled with debt service and negative cash flow as wholesale prices remained below break-even levels. According to industry analysts, cultivation facilities require wholesale prices above $1,200 per pound to cover operating expenses, debt service, and regulatory compliance costs for indoor operations, while current market prices of $800-$1,000 per pound leave insufficient margin. License concentration has increased as larger operators acquire distressed assets. Multi-state operators have purchased approximately 40 cultivation licenses and 25 retail licenses from financially stressed Michigan operators since 2023, according to CRA transfer records. This consolidation mirrors patterns in mature markets including Colorado, Oregon, and Washington, where initial license proliferation gave way to market rationalization. Tax revenue provides fiscal benefits to state and local governments. Michigan collected approximately $290 million in cannabis excise and sales tax revenue during fiscal year 2025, with funds allocated to education (35%), transportation infrastructure (35%), municipalities hosting cannabis businesses (15%), and the Cannabis Regulatory Agency (15%) under MRTMA provisions. Detroit, Ann Arbor, and other municipalities collect additional local taxes ranging from 1-3% of gross receipts. Employment impacts remain significant despite consolidation. The Michigan cannabis industry employed approximately 35,000 workers as of December 2025, including cultivation technicians, budtenders, processors, delivery drivers, and administrative staff. Wages average $15-$18 per hour for entry-level positions and $50,000-$80,000 annually for management roles. The May 2026 Lansing layoffs represent approximately 0.3% of total industry employment but signal vulnerability in the cultivation sector. Capital markets have largely withdrawn from Michigan cannabis investments. After significant capital inflows from 2019-2021, institutional investors have reduced exposure to cannabis operators facing federal illegality and margin compression. Debt financing remains available but at elevated interest rates of 12-18% annually, compared to 8-12% in 2020. Equity raises have become difficult for all but the largest MSOs with multi-state operations providing portfolio diversification.

State-by-State Context

Michigan's open-license approach contrasts sharply with limited-license models in neighboring states, creating competitive advantages for consumers but challenges for operators.

Michigan

Michigan maintains approximately 1,800 active cannabis licenses as of May 2026, including roughly 850 cultivation licenses, 650 retail licenses, 200 processor licenses, and 100 licenses across testing, transport, and other categories. The state imposes no caps on license numbers beyond standard regulatory requirements. Retail prices average $30-$35 per eighth-ounce of flower, among the nation's lowest. Medical patients may possess 2.5 ounces and cultivate 12 plants; adult-use consumers may possess 2.5 ounces in public, 10 ounces at home, and cultivate 12 plants per household.

Illinois

Illinois operates a limited-license model with approximately 185 retail licenses and 40 cultivation licenses as of 2026. This artificial scarcity maintains elevated prices, with retail eighths averaging $55-$65 before taxes. Illinois imposes a tiered excise tax based on THC content (10% for products under 35% THC, 20% for cannabis-infused products, 25% for concentrates above 35% THC) plus standard sales tax, resulting in effective tax rates of 30-40%. Adult-use consumers may possess 30 grams (approximately one ounce) of flower. Medical patients may possess 2.5 ounces over 14 days.

Ohio

Ohio legalized adult-use cannabis through Issue 2 in November 2023, with sales commencing in 2024. The state initially authorized approximately 130 adult-use retail licenses, building on the existing medical framework established in 2016. Retail prices average $40-$45 per eighth-ounce. Ohio permits adult possession of 2.5 ounces and home cultivation of six plants per individual (12 per household). The state imposes a 10% excise tax on adult-use sales.

New York

New York's adult-use market launched in December 2022 but has struggled with slow licensing and illicit competition. The state has issued approximately 150 adult-use retail licenses as of May 2026, far below initial projections. Retail prices at legal dispensaries average $50-$60 per eighth-ounce, while illicit storefronts undercut legal operators. New York permits adult possession of three ounces of flower and 24 grams of concentrate, with home cultivation prohibited. The state imposes a 13% excise tax plus local taxes.

California

California, the nation's largest cannabis market, generated approximately $5.3 billion in legal sales during 2025. The state maintains an open-license structure with over 1,200 retail licenses and 2,500 cultivation licenses. Retail prices average $35-$40 per eighth-ounce in competitive markets. California permits adult possession of one ounce of flower and eight grams of concentrate, with home cultivation of six plants. The state imposes a 15% excise tax on retail sales, though tax rates have been reduced from earlier levels to improve competitiveness with illicit markets. Michigan's regulatory approach most closely resembles California and Colorado in permitting open licensing, contrasting with limited-license states like Illinois and New York. This structural difference explains Michigan's lower consumer prices but also the oversupply pressures driving facility closures like the May 2026 Lansing operation.

What Experts Say

Industry analysts and operators attribute Michigan's consolidation phase to predictable market dynamics that follow rapid license proliferation in open-license states. According to Andrew Brisbo, former executive director of the Michigan Cannabis Regulatory Agency who led the agency from 2019-2022, the state intentionally designed an open-license system to prioritize consumer access and prevent monopolistic control. In public statements during his tenure, Brisbo emphasized that Michigan's approach would create competitive markets with lower prices, while acknowledging that some operators would struggle as markets matured. Cannabis industry analyst Matt Karnes of GreenWave Advisors has noted that Michigan's wholesale price compression follows patterns observed in Colorado and Oregon, where cultivation license proliferation created sustained oversupply. In research reports published in 2024-2025, Karnes projected continued consolidation in Michigan's cultivation sector, with 20-30% of licenses likely to be surrendered or acquired by larger operators by 2027. Robin Schneider, executive director of the Michigan Cannabis Industry Association, has advocated for regulatory reforms to support struggling operators, including potential cultivation license caps and tax relief. In testimony before the Michigan Legislature in 2025, Schneider argued that unlimited cultivation licensing created unsustainable market conditions, though she acknowledged that license caps would face legal and political challenges under the MRTMA's structure. Operators have expressed mixed perspectives. Vertically integrated companies with retail operations have weathered price compression more successfully than cultivation-only operators. According to financial disclosures from publicly-traded MSOs operating in Michigan, retail operations maintained positive EBITDA margins of 15-25% through 2025, while standalone cultivation operations reported negative margins. Local government officials in communities hosting cannabis businesses have expressed concern about facility closures and layoffs. Lansing Mayor Andy Schor, responding to the May 2026 cultivation facility closure, stated that the city would work with affected employees to connect them with other opportunities in the region's growing cannabis sector, while acknowledging that market consolidation creates economic disruption. Patient advocates have emphasized that Michigan's low prices benefit medical cannabis patients, many of whom live on fixed incomes. According to data from patient surveys conducted by advocacy organizations, Michigan medical patients spend an average of $150-$200 monthly on cannabis medicine, compared to $300-$400 in limited-license states, making treatment more accessible.

What's Next

Michigan's cannabis market will likely stabilize around current sales levels of $3-3.2 billion annually through 2027, with continued consolidation in the cultivation sector and potential regulatory reforms addressing oversupply. Several developments will shape the market's trajectory: **Federal rescheduling**: The U.S. Drug Enforcement Administration's ongoing review of cannabis scheduling could result in reclassification from Schedule I to Schedule III under the Controlled Substances Act. If implemented, rescheduling would eliminate 280E tax burdens, potentially improving operator profitability by 15-25% according to industry estimates. The DEA's administrative law judge hearing process, initiated in 2024, continues with no definitive timeline for final action. **Social consumption implementation**: Michigan authorized designated consumption establishments in 2021, but implementation has proceeded slowly. As of May 2026, fewer than 10 social consumption licenses have been issued statewide. Municipalities including Detroit and Ann Arbor are developing local frameworks, with additional licenses expected in 2026-2027. Social consumption venues could create new revenue streams for operators and expand consumer access. **Interstate commerce**: Legal challenges to state-level prohibitions on interstate cannabis commerce continue in federal courts. If courts strike down interstate commerce barriers, Michigan's low-cost production could position the state as a regional supplier to higher-price markets, though such developments remain speculative and face significant legal hurdles. **Municipal opt-ins**: Approximately 1,400 Michigan municipalities currently prohibit cannabis businesses. Gradual opt-ins by additional communities would expand market access and potentially support additional retail licenses, though cultivation oversupply would likely persist. **Regulatory reforms**: The Michigan Legislature may consider reforms to address market conditions, including potential cultivation license caps, tax reductions, or streamlined licensing processes. However, any changes to the MRTMA's core provisions would require voter approval under Michigan's constitutional framework for citizen-initiated laws. **Continued consolidation**: Industry analysts project that Michigan's cultivation license count will decline to 600-700 licenses by 2027, down from a peak of approximately 1,000 in 2022. Retail consolidation will likely proceed more slowly, with license counts stabilizing around 600-650 locations. Multi-state operators will continue acquiring distressed assets, increasing market concentration. **Product innovation**: Operators are investing in product differentiation through genetics, processing techniques, and brand development. Premium indoor flower, solventless concentrates, and strain-specific products command price premiums of 20-40% over commodity products, providing margin opportunities for quality-focused operators. The May 2026 Lansing facility closure signals that Michigan's consolidation phase continues, but the market's overall stability around $3 billion in annual sales suggests that the most severe disruption has passed. Operators that survive this rationalization period will enter a more sustainable competitive environment with improved supply-demand balance.

Further Reading

• Michigan Cannabis Regulatory Agency official website: https://www.michigan.gov/cra
• Michigan Regulation and Taxation of Marihuana Act (MRTMA) full text: https://www.legislature.mi.gov/documents/mcl/pdf/mcl-Initiated-Law-1-of-2018.pdf
• Michigan Medical Marihuana Act (MMMA) full text: https://www.legislature.mi.gov/documents/mcl/pdf/mcl-333-26421.pdf
• Michigan Cannabis Regulatory Agency monthly sales data: https://www.michigan.gov/cra/adult-use/data
• Michigan Legislature cannabis statute database: https://www.legislature.mi.gov
• Michigan Cannabis Industry Association: https://www.michigancannabisindustry.org
• Detroit adult-use cannabis program information: https://detroitmi.gov/departments/civil-rights-inclusion-opportunity-department/detroit-cannabis
• U.S. Drug Enforcement Administration cannabis scheduling docket: https://www.regulations.gov

Update — June 1, 2026: Rural Michigan Dispensaries Face Closure Pressure from Tax Burden and Market Saturation

Cannabis retailers in rural Michigan communities faced mounting pressure to close or relocate as combined state and local tax rates exceeded 16% in some jurisdictions, according to operators in Washtenaw and Jackson counties. Small-town dispensaries reported difficulty competing with urban markets where higher customer volume offset similar tax obligations. The Manchester Mirror documented at least three provisioning centers in towns under 5,000 population that ceased operations in May 2026, citing unsustainable overhead relative to daily transaction counts.

The consolidation trend reflected broader market dynamics as Michigan's licensed retailer count surpassed 850 active provisioning centers statewide, creating dense competition in metropolitan areas while leaving rural operators with insufficient customer bases. Operators said the 10% state excise tax combined with municipal taxes ranging from 0% to 6% created effective rates that eroded margins on lower-volume sales. One Washtenaw County dispensary owner said monthly revenue of $75,000 generated insufficient profit after tax remittance, rent, and compliance costs.

The shift carried implications for patient access in underserved regions where the nearest alternative dispensary could be 30 or more miles away. Rural municipalities that enacted local cannabis taxes to fund infrastructure projects now faced the prospect of losing that revenue stream entirely if remaining operators closed. Industry observers noted the pattern mirrored consolidation in other mature cannabis markets where economies of scale favored multi-location operators over single-site businesses.

Michigan's Cannabis Regulatory Agency reported provisional license surrenders increased 22% year-over-year through May 2026, with the majority occurring in communities with populations below 10,000. The agency attributed the trend to market maturation rather than regulatory changes, as licensing requirements remained stable since 2024. Analysts said the rural exodus could accelerate if wholesale prices continued declining, further compressing margins for low-volume retailers unable to negotiate bulk purchasing discounts.

Update — June 5, 2026: Companies Exit Michigan Despite $3 Billion Market

Despite Michigan's cannabis market reaching $3 billion in annual sales, multiple licensed operators began exiting the state in early 2026, according to industry reports compiled by MITechNews. The exodus occurred even as Michigan maintained its position as one of the nation's largest adult-use markets by revenue, raising questions about profitability margins and regulatory burden.

Operators cited compressed wholesale prices, which fell below $1,000 per pound for flower in several regional markets, alongside rising compliance costs tied to Michigan's Cannabis Regulatory Agency oversight requirements. Oversupply conditions persisted as the state's licensed cultivation canopy expanded faster than retail infrastructure, creating a structural imbalance between production capacity and consumer access points.

The departures included both multi-state operators consolidating footprints and Michigan-based cultivators shuttering facilities. Several companies transferred licenses to new ownership rather than renewing annual permits, according to CRA transfer records. Tax collections remained strong, however, with the state reporting no decline in excise revenue through the first quarter of 2026.

Industry analysts said the trend reflected market maturation dynamics common to states with open licensing structures and minimal barriers to entry. Michigan issued over 1,800 active licenses across cultivation, processing, and retail categories by mid-2026, creating intense competition that favored vertically integrated operators with economies of scale. The exits suggested smaller single-license businesses faced unsustainable margins despite robust consumer demand.

For investors, the Michigan market illustrated the gap between top-line sales growth and operator profitability. Companies remaining in the state focused on cost reduction, automation investments, and retail channel expansion to maintain viability in the compressed-margin environment.

Update — June 11, 2026: Medical cannabis market share concerns prompt industry debate

Michigan's medical cannabis program faced renewed scrutiny as recreational sales continued to dominate the state's $3 billion cannabis market, according to industry analysts cited by Crain's Detroit. Medical dispensaries reported declining patient enrollment and reduced foot traffic as adult-use retailers captured approximately 78 percent of total state cannabis revenue in the first quarter of 2026. The shift raised questions about the long-term viability of Michigan's dual-market structure, which has operated since recreational sales launched in December 2019.

Industry stakeholders pointed to lower excise tax rates for medical purchases—6 percent versus 10 percent for recreational—as insufficient incentive to maintain patient registrations. Medical cardholders in Michigan numbered approximately 285,000 in early 2026, down from a peak of 340,000 in 2021, according to state Cannabis Regulatory Agency data. Operators said the $60 annual registration fee and required physician certification deterred price-sensitive consumers who could access similar products through adult-use channels without administrative barriers.

Patient advocates emphasized that medical cardholders retain higher possession limits of 2.5 ounces versus 2.5 ounces for recreational users and access to higher-potency products not available in adult-use stores. Several medical-focused dispensaries reported stable revenue from patients managing chronic conditions who valued consistent product availability and specialized consultation services. Operators serving both markets said medical sales provided margin stability during periods of recreational price compression driven by oversupply.

The debate intensified as lawmakers considered proposals to eliminate the medical registration fee or expand qualifying conditions to preserve the program's distinct role. Industry groups warned that collapsing the medical market entirely would eliminate protections for patients with serious health conditions and reduce product diversity. The discussion reflected broader tensions in mature cannabis markets balancing commercial growth with therapeutic access, a pattern observed in Colorado, Oregon, and other dual-license states where recreational sales eclipsed medical programs within five years of adult-use legalization.

Update — June 24, 2026: Medical marijuana sales collapse to $322,350 amid patient exodus to adult-use market

Michigan's medical marijuana program recorded just $322,350 in total sales during a recent reporting period, according to state data released June 24, 2026, marking a historic low as patients continue migrating to the adult-use market. The figure represents a dramatic decline from medical program peaks that once exceeded $10 million monthly before adult-use sales launched in December 2019.

The collapse reflects structural incentives favoring recreational purchases over medical card renewals. Adult-use dispensaries now outnumber medical-only facilities across the state, offering comparable product selection without the $60 annual physician certification fee or the $40 state registry card cost. Industry analysts said the medical program now serves primarily patients seeking higher possession limits or specific tax exemptions unavailable in the recreational market.

The timing coincides with intensifying federal debate over cannabis rescheduling from Schedule I to Schedule III under the Controlled Substances Act. Rescheduling would not legalize recreational cannabis federally but could alter tax treatment under Internal Revenue Code Section 280E, which currently prohibits state-legal cannabis businesses from deducting ordinary expenses. Michigan operators said federal policy uncertainty has not slowed adult-use expansion, with the state's recreational market generating over $3 billion in cumulative sales since inception.

State regulators have not announced plans to consolidate or eliminate the medical program despite dwindling participation. Approximately 264,000 active medical cards remained registered as of early 2026, down from a 2018 peak near 300,000, according to Michigan Marijuana Regulatory Agency data. The agency said medical program infrastructure continues operating to serve patients with specific therapeutic needs and those in municipalities that prohibit adult-use sales but permit medical dispensaries.